Original Article

Pain Controlling and Cytokine-regulating Effects of Lyprinol, a Lipid Extract of *Perna Canaliculus*, in a Rat Adjuvant-induced Arthritis Model

Chi-Ho Lee¹, John Hon-Kei Lum¹, Curtise Kin-Cheung Ng², Janice McKay², Yoki Kwok-Chu Butt¹, Man-Sau Wong¹ and Samuel Chun-Lap Lo¹

¹State Key Laboratory of Chinese Medicine and Molecular Pharmacology, Shenzhen and Department of Applied Biology and Chemical Technology and ²Department of Health Technology and Informatics, Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong SAR, China

Using an adjuvant-induced arthritis rat model, we investigated the effects of a lipid extract of *Perna canaliculus* (Lyprinol®/C213) on pain. Radiological examinations, as well as levels of pro- and anti-inflammatory (AI) cytokines, were measured aiming to provide independent objective data to the pain controlling investigation. We confirmed the ability of Lyprinol® to control pain at the initial phase of its administration; with similar efficacy to that observed with Naproxen. The pain scores slowly increased again in the group of rats treated with Lyprinol® after day 9–14. The Naproxen-treated rats remained pain-free while treated. Both Naproxen and Lyprinol® decreased the levels of the pro-inflammatory cytokines TNF-α and IFN-γ, and increased that of IL-10. Extra-virgin olive oil was ineffective on cytokine secretion. Rats treated with Lyprinol® were apparently cured after 1 year. This study confirms the AI efficacy of this lipid extract of *P. canaliculus*, its initial analgesic effect, its perfect tolerance and its long-term healing properties.

Keywords: adjuvant-induced arthritis – inflammatory cytokines – Lyprinol® – NZGLM, pain score

Introduction

Lipid Extract of New Zealand Green-lipped Mussel (Lyprinol®)

A lipid-rich and stabilized extract of New Zealand green-lipped mussel *Perna canaliculus* powder (NZGLM, Lyprinol®), has been shown to have significant anti-inflammatory (AI) activity when given to animals and humans (1–11). This article contributes to the emerging literature on bioprospecting (12). This approach seeks to emphasize for complementary and alternative medicine (CAM) the utility of products derived from animals in treating certain diseases (13–17). Lyprinol® is a mixture of five main lipid classes including sterol esters, triglycerides, free fatty acids, sterols and polar lipids (18,19). There are 90 component fatty acids in Lyprinol® (18,19). Omega-3 polyunsaturated fatty acids are one of the most abundant PUFAs. Eicosapentaenoic acid (20 carbons and 5 double bonds, shorthand = 20 : 5 omega-3) (EPA) and docosahexaenoic acid (22 : 6 omega-3) (DHA) are the major omega-3 PUFAs present in Lyprinol.

Anti-inflammatory Effects

Although the exact active ingredients that brought about this AI effect are unknown, Whitehouse et al. (3) reported that Wistar and Dark Agouti rats treated p.o. with this lipid extract did not develop adjuvant-induced polyarthritis or collagen (II)-induced auto-allergic arthritis. This was achieved with doses inferior to the ones...
of NSAIDs, and 200 times lower than other seed or fish oils (3). Further, omega-3 PUFA subfractions of this lipid extract inhibited LTB4 biosynthesis by neutrophils in vitro, and PGE2 production by activated macrophages (20). Subfractions of this extract containing natural antioxidants (e.g. carotenoids) also exhibited AI activity (5). In contrast to NSAIDs, Lyprinol® is non-gastro-toxic in disease-stressed rats at 300 mg kg−1 p.o. (3), and does not affect platelet aggregation in both humans and rats (3).

Clinical studies, either controlled or randomized, have demonstrated that Lyprinol® has highly significant AI activity in patients with osteoarthritis (OA) (4,7,8,21), asthma (22) and other inflammatory conditions (10). Therefore, it seems that Lyprinol® is a reproducible, stable source of bioactive lipids with much greater potency than plant/marine oils currently used as nutritional supplements to ameliorate signs of inflammation (3,10,23). More importantly, in humans and animal subjects taking Lyprinol®, there are no reported side-effects, even at doses up to 2500 mg per day in patients.

Given the AI activities of Lyprinol®, we were interested to know if these AI effects could be translated into pain-controlling effects. We conducted a series of experiments to understand the AI mechanism of action of this lipid extract. This article reports our findings on the pain-controlling ability of Lyprinol at the initial phase of its administration. This ability is similar to the one observed with Naproxen. Cytokine levels in/from splenocytes of these animals, as well as radiological examination of the affected joints, were also measured to bring objective confirmation to the pain controlling investigation.

Methods

Chemicals

Unless stated otherwise, all chemicals were purchased from Sigma (St Louis, MO, USA). All chemicals were at least of AR grade. Organic solvents used were at least of HPLC grade.

Induction of Inflammation in Sprague-Dawley Rats

Four groups of six 6-week-old male Sprague-Dawley (SD) rats (normal group, adjuvant-induced arthritis (AIA) group, AIA + Naproxen group and AIA + Lyprinol group) and two groups of three 6-week old SD rats (AIA group and AIA + long-term Lyprinol feeding group, respectively) were purchased from the Central Animal Facility (CAF) of Hong Kong Polytechnic University (HKPU). All rats were kept and cared under conditions that fully met requirements of Procedures for the Care of Laboratory Animals or Animals (Control of Experiments) Regulations Chapter 340 of the Hong Kong SAR government. Ethics approval (ASESC No.04/9) was from The Animal Subjects Ethics subcommittee of the HKPU. Arthritis was induced in anesthetized rats by administration of adjuvant according to a method previously described (24,25). Briefly, on Day 0, each rat was injected into the paw of the right hind limb with 100 μl of Freund’s complete adjuvant containing 10 mg ml⁻¹ of Mycobacterium butyricum (Difco, Livonia, MI, USA). Another six rats without arthritis induction were observed as a normal group.

Products/Drug Tested Fed to the Treatment and Control Groups of Rats

Rats in the Lyprinol® (Pharmalink International Ltd, Burleigh Heads, QLD, Australia) group were fed by oral gavage at a dosage of 25 mg Lyprinol kg⁻¹ body weight. Typically, the required amount of Lyprinol was made up with olive oil (Virgin®, Bertolli, Italy) to 300 μl and then force-fed to the rats with a stainless steel stomach tube. Three hundred micro liters of olive oil, and 20 mg kg⁻¹ body weight of Naproxen were fed as vehicle and positive control. Normal chow was provided to all rats. Except for the long-term Lyprinol-feeding group, feeding of Lyprinol, olive oil and Naproxen were discontinued after the experimental period of 28 days. For the long-term Lyprinol-feeding group, the required amount of diluted Lyprinol (to a dosage of 25 mg kg⁻¹ body weight) was added onto 25 g of dry rat chow. These chows were fed to rats daily. Once these chows were completely consumed, normal chows were given.

Pain Score Measurement

The measurement of pain score was performed according to Hayashida et al. (26). The number of pain-related responses, represented by vocalizations, was recorded during 10 flexions of the tarsotibial joints of the adjuvant-injected paw. Results were expressed as the mean number of vocalizations.

Splenocyte Preparation

At Day 14 and 28 after arthritis induction, splenocytes of each rat of group P. canaliculus, Naproxen, olive oil and control were prepared as described previously (27). Briefly, spleens were removed aseptically and minced into tiny pieces. Single cell suspensions were prepared by gentle grinding of spleen pieces in RPMI 1640 medium (Life Technologies, US). Splenocytes (mostly B- and
T-cells) from the crude spleen cell suspension were recovered by using Ficoll-Hypaque® Plus lymphocyte isolation kit (Pharmacia Biotech, USA) as described in the manufacturer’s manual. Recovered splenocytes (1.5 ml) were transferred into a sterile centrifuge tube and four volumes of pre-chilled 0.83% ammonium chloride (NH₄Cl) was added and incubated for 10 min for lysis of residual erythrocytes (28). Splenocytes were recovered by centrifugation at 3000 rpm for 5 min, washed with 8 ml pre-warmed (37°C) sterile PBS buffer (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na₂HPO₄·7H₂O, 1.4 mM KH₂PO₄, pH 7.4) and finally resuspended in appropriate volume of complete RPMI 1640 medium (10% fetal bovine serum, 100 units ml⁻¹ of penicillin and 100 µg ml⁻¹ of streptomycin, supplemented with 0.3 mg/ml L-glutamine and 25 mM HEPES).

**Cell Count and Viability Staining**

Resuspended splenocytes were stained with 0.4% Trypan blue exclusion dye (0.4 g Trypan blue in 100 ml PBS buffer) at ratio 1: 1. Number of splenocytes was counted and calculated with the aid of a hemocytometer. More than 99% of splenocytes were viable. Except stated otherwise, splenocytes were diluted to a working population of 5 × 10⁶ cells ml⁻¹ in all experiments.

**ELISA Assay for Cytokines**

A total of 5 × 10⁶ splenocytes ml⁻¹ were seeded in 24-well plate; a suboptimal concentration (1.25µg ml⁻¹) of lipopolysaccharide (LPS) (Sigma, St Louis, MO, USA) was used to prime the splenocyte culture. Splenocytes were incubated in 37°C incubator with 80% humidity and 5% CO₂ atmosphere condition. Supernatant was collected at 10 and 24h after LPS activation and stored at −80°C until later measurement. Interleukin-10 (IL-10), tumor necrosis factor-alpha (TNF-α) and interferon-gamma (IFN-γ) were measured by enzyme-liked immuno-sorbent assay (ELISA) (BioSource, CA, USA) as described in the user’s manual.

**Statistical Analysis**

Experimental data were compared to the ones of the control group and analyzed by Student’s t-test with one way ANOVA.

**Results**

**Photographic and Radiographic Analysis of AIA Rat Paws**

Figure 1 shows photographs of the right hind paw of rat at different times after AIA induction. Figure 1A was taken at 14 days after AIA induction. Swelling of the whole right hind paw, especially around the tarsotibial joints, is significant as shown in the photo. X-ray photography of the same paw at Day 21 after AIA reveals severe peritubicular soft tissue swelling, joint subluxation and periostal new bone formation (Fig. 1B). The degree of arthritis between control group and Lyprinol® group shows no difference during the whole 28-day course of the experiment. However, 1 year after the induction of AIA, deformation of joints and lesions are still observable in the olive oil-control group (Fig. 1C). Conversely, deformation of joints and lesions are not visible in the Lyprinol®-long-term treatment group (Fig. 1D).
Pain Score Measurement

Pain score measurement is a widely used and reliable method to reflect the effectiveness of different treatments on AIA (26). It is one of the commonly used methodologies to measure level of pain (29,30,31). As shown in Fig. 2, the NSAID Naproxen effectively maintained the pain score of AIA rats at a relatively low level during the whole course of the experiment. Compared to the ones of the control and olive oil-treated groups, Lyprinol® effectively lowered the pain score of AIA rats from Day 4 to Day 26 after induction of arthritis. The effect of Lyprinol® was most pronounced between Day 4 and Day 12, with an effect comparable to that of Naproxen. The effect of Lyprinol® began to wane after Day 14, but still maintained the pain score at a significantly lowered level when compared to the control and olive oil-treated groups. Our results clearly demonstrated that Lyprinol® is very useful in controlling pain of severe arthritis, especially during the early and intermediate phase of AIA.

Level of Pro-inflammatory Cytokines Tumor Necrosis Factor-alpha and interferon-gamma

At Day 14 after induction of arthritis, splenocytes from Lyprinol®-fed rats were harvested and pro-inflammatory cytokines levels were determined. As shown in Fig. 3, TNF-α level of Lyprinol® group was greatly decreased from 3.07 ± 0.168 to 1.71 ± 0.405 ng ml⁻¹. Besides, production of another pro-inflammatory cytokine, IFN-γ, was significantly decreased. As shown in Fig. 4, the IFN-γ level of the Lyprinol® group, when compared to control, was dramatically decreased from level 10.7 ± 0.8 to 3.0 ± 0.9 ng ml⁻¹.

Level of Anti-inflammatory Cytokine Interleukin-10

Figure 5 shows that the AI cytokine IL-10 increased at Day 28 after AIA. Although there is no statistically significant difference between the levels observed in the control group and the Lyprinol® group, the increase of IL-10 in the Lyprinol® group almost reached levels observed in the positive control group (Naproxen).

Discussion

Pain score measurement is a widely used and reliable method to reflect the effectiveness of different treatments on AIA (26). It is one of the commonly used methodologies to measure level of pain. AIA in the rat is a standard model accepted for the study of inflammation and its control by medications or supplements (32). We used this model in order to get a better understanding...
of mechanisms resulting in AI effects of the lipid extract of *P. canaliculus*, the green-lipped mussel from New Zealand (Lyprinol®). A number of studies have been reported and/or published on this product in terms of its composition, its effects when compared with other drugs or lipids of diverse origins, its efficacy in several animal models and its effects on symptoms of OA and asthma.

Since the major complaint of patients suffering from acute exacerbations of chronic inflammatory disease is pain, we evaluated the analgesic effect of the lipid extract in the AIA rat model. We also measured levels of pro-inflammatory and anti-inflammatory cytokines. We compared results observed of Lyprinol, with a sham group (no drugs), an olive oil group (negative control), a non-steroid AI drug (NSAID) and a Naproxen (positive control) group. We also observed a group of rats as reference that were not treated with adjuvant.

Recent studies on pain, both in humans (33–36) and animals (34,37,38) have demonstrated the active role of IL-6 in inducing pain, as well as IL-1β, IL-8, TNF-α (TNF-R1 receptor) and IFN-γ. Conversely, IL-10 is associated with control of pain.

Lyprinol® exhibits a significant effect controlling pain in several recent clinical studies. The group at the University of Hong Kong (8) conducted the first randomized controlled trial to evaluate the effects of Lyprinol®, on signs and symptoms and quality of life (QOL) of patients with knee OA. Their results showed that Lyprinol® over 6 months in patients with knee OA is perfectly tolerated and associated with a decrease in pain perception after 2 months when compared to placebo.

The visual analog scale (VAS) for pain score was significantly reduced from 63.0 at baseline to 55.5 at Week 4 (*P* = 0.046), 51.2 at Week 8 (*P* = 0.003) and 49.7 at Week 12 (*P* = 0.001). There was a greater significant reduction in VAS pain score following adjustment for change in amounts of paracetamol (acetaminophen) used in patients who received the lipid extract when compared with controls at Week 8 (*P* = 0.035), Week 12 (*P* = 0.032) and Week 24 (*P* = 0.045).

Another multi-center clinical study in Korea on patients with OA of the hip and knee found that the average VAS score, Lequesne functional index, global assessment by patients and global assessment by physician were all significantly improved (7). After a 4- and 8-week treatment period, 53–80% of patients experienced significant pain relief, and improvement of joint function. There was no reported adverse effect during this clinical trial (7).

A third study was conducted in Germany on 50 adults with inflammatory rheumatoid arthritis (21). The number of painful joints was reduced from 4.18 ± 2.80 at baseline to 3.00 ± 2.14 points (72%) after 6 weeks and 0.60 ± 1.18 points (14.4%) after 12 weeks (*P* = 0.012 and *P* = 0.001). For a sub-parameter ‘number of painful small joints’, a highly significant reduction of 9.3% after 6 weeks and 18.6% after 12 weeks was observed (*P* = 0.022 and *P* = 0.002). Analgesic medications were reduced or stopped in 21 subjects who required these at the beginning of the trial.

Our study of the mean pain score measurement by ten flexions of the tarsotibial joints of adjuvant-injected paw (*n* = 6) did demonstrate a significant reduction of pain in AIA rats treated with Lyprinol®, or Naproxen. However, this reduction differed according to the product used to treat the rats: pain scores in Naproxen and Lyprinol® groups initially increased; but they decreased significantly and gradually in the Lyprinol® group to reach a nadir (score = 2) at Day 8, while rats in the Naproxen group experienced a more erratic pain reduction with a significant nadir (score = 0) at Day 9. However, the pain score started differing significantly after Day 9: the Lyprinol® group experienced a progressive increase in pain scores, reaching its initial level at Day 15; while the Naproxen group remained essentially pain-free during the rest (total days = 26) of the experiment. This curve, transposed to the human time scale, is quasi-identical to the pain scale observed by Lau *et al.* (8) where the maximum reduction in pain was observed after approximately 8–12 weeks of treatment in patients with OA. It may well be due to an ‘escape’ mechanism from the production of pro-inflammatory cytokines that tend to increase despite treatment with Lyprinol®; it may also be due to other inflammatory mechanisms of AIA (and/or OA).

The cause of pain severity was confirmed by aspects of the inflamed paw when compared with the non-injected one, and comparative radiological images. X-rays confirmed the presence of major osteo-cartilaginous destruction as well as major swelling of the affected paw.

Pro-inflammatory cytokine production (TNF-α, IFN-γ) was significantly controlled by Lyprinol® (Day 14), as well if not better than Naproxen. IL-10, an ‘anti-inflammatory’ cytokine was increased in the Lyprinol® and in the Naproxen group, but did not reach statistical significance. Extra-virgin olive oil was ineffective in our study.
More importantly, after 1 year, rats that were treated with Lyprinol® had a normal AIA paw, while untreated rats had severe inflammatory, ulcerative lesions.

**Conclusion**

The lipid extract of *P. canaliculus* is known as a powerful AI product in animal models and human diseases (asthma, arthritis). We have confirmed in the adjuvant-AI product in animal models and human diseases.

**Acknowledgements**

Prof. Georges M. Halpern (MD, PhD) initiated this study; organized it and helped to shape the manuscript. He should have been the leading author. We thank Pharmalink International Company Ltd, Burleigh Heads, QLD, Australia, for supplying the lipid extract of *P. canaliculus* (Lyprinol®) and the placebo, and for an unrestricted educational and research grant that supported our study in part.

**References**

4. Gibson SL, Gibson RG. The treatment of arthritis with a lipid extract of *P. canaliculus* (Lyprinol®) and the placebo, and for an unrestricted educational and research grant that supported our study in part.


Received November 9, 2006; accepted July 10, 2007